Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 0.85 |
| ▸ | SLC16A3 | O15427 | 3/20 | 0.80 |
| ▸ | MAOA | P21397 | 6/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | CA4 | P22748 | 1/20 | 0.63 |
| ▸ | CA5A | P35218 | 1/20 | 0.63 |
| ▸ | CA7 | P43166 | 1/20 | 0.63 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22148003 | 0.92 | MAOB (1.00) | MAOBSLC16A3MAOACA12CA1 | |
| SCHEMBL93418 | 0.89 | MAOB (0.80) | MAOBSLC16A3MAOA | |
| SCHEMBL93260 | 0.89 | SLC16A3 (1.00) | MAOBSLC16A3MAOACA12CA1 | |
| SCHEMBL30023219 | 0.87 | SLC16A3 (0.82) | MAOBSLC16A3MAOACA12CA1 | |
| SCHEMBL28295864 | 0.86 | MIF (0.72) | MAOBSLC16A3MAOA | |
| SCHEMBL3366496 | 0.85 | POLB (0.71) | MAOBSLC16A3CA12CA1CA4 | |
| SCHEMBL3589538 | 0.83 | MAOB (0.84) | MAOBSLC16A3MAOACA12CA1 | |
| SCHEMBL2910106 | 0.81 | SLC16A3 (0.64) | MAOBSLC16A3 | |
| SCHEMBL4758088 | 0.80 | SLC16A3 (0.81) | MAOBSLC16A3MAOACA12CA1 | |
| SCHEMBL10533969 | 0.79 | MAOB (0.77) | MAOBSLC16A3MAOACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611912-B1 | NOVEL MONOOXYGENASE VARIANTS | BRAIN BIOTECHNOLOGY RES & INFORMATION NETWORK AG (DE) | 2016-11-02 | — | — | EP | disclosed |
| EP-2611912-B1 | NOVEL MONOOXYGENASE VARIANTS | BRAIN BIOTECHNOLOGY RES & INFORMATION NETWORK AG (DE) | 2016-11-02 | — | — | EP | disclosed |
| US-20160115146-A1 | 3-CARBOXY SUBSTITUTED COUMARIN DERIVATIVES WITH A POTENTIAL UTILITY FOR THE TREATMENT OF CANCER DISEASES | CISTIM (BE) | 2016-04-28 | — | — | US | disclosed |
| US-20160115146-A1 | 3-CARBOXY SUBSTITUTED COUMARIN DERIVATIVES WITH A POTENTIAL UTILITY FOR THE TREATMENT OF CANCER DISEASES | CISTIM (BE) | 2016-04-28 | — | — | US | disclosed |
| EP-2426198-A1 | Cytochrome P450 monooxygenase variants | B.R.A.I.N. Biotechnology Research And Information Network AG (DE) | 2012-03-07 | — | — | EP | disclosed |
| EP-2426198-A1 | Cytochrome P450 monooxygenase variants | B.R.A.I.N. Biotechnology Research And Information Network AG (DE) | 2012-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115146-A1 | 3-CARBOXY SUBSTITUTED COUMARIN DERIVATIVES WITH A POTENTIAL UTILITY FOR THE TREATMENT OF CANCER DISEASES | SLC16A3, SLC16A1, SLC16A8 | MAOB 3418/4885SLC16A3 1/4885MAOA 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.